Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept vs belimumab for active lupus nephritis (real‑world cohort)
ChiCTR2200063739Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of telitacicept and belimumab in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (2 cohorts), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Proportion of patients achieving primary renal efficacy response (PERR). Planned start Aug 2022; status: not yet recruiting.
02
Drugs
telitaciceptbelimumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2200063739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063739.